Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, has announced that…
Tag: Clinical Trials / Drug Trials
TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory…